Roivant Sciences Ltd.
Index- P/E- EPS (ttm)-1.60 Insider Own0.50% Shs Outstand686.59M Perf Week10.07%
Market Cap3.16B Forward P/E- EPS next Y-1.46 Insider Trans-16.35% Shs Float420.58M Perf Month14.63%
Income-1084.80M PEG- EPS next Q-0.32 Inst Own50.50% Short Float0.86% Perf Quarter-1.67%
Sales61.20M P/S51.71 EPS this Y-35.50% Inst Trans2.45% Short Ratio4.40 Perf Half Y-60.24%
Book/sh2.72 P/B1.73 EPS next Y-0.70% ROA- Target Price12.00 Perf Year-52.53%
Cash/sh3.29 P/C1.43 EPS next 5Y- ROE- 52W Range2.52 - 16.76 Perf YTD-53.37%
Dividend- P/FCF- EPS past 5Y- ROI-48.60% 52W High-71.96% Beta-
Dividend %- Quick Ratio14.20 Sales past 5Y- Gross Margin85.30% 52W Low86.51% ATR0.40
Employees665 Current Ratio14.20 Sales Q/Q319.00% Oper. Margin- RSI (14)60.54 Volatility9.27% 10.14%
OptionableYes Debt/Eq0.11 EPS Q/Q0.00% Profit Margin- Rel Volume0.85 Prev Close4.68
ShortableYes LT Debt/Eq0.11 EarningsJun 28 BMO Payout- Avg Volume817.72K Price4.70
Recom1.70 SMA2012.53% SMA5020.88% SMA200-28.98% Volume690,647 Change0.43%
May-23-22Initiated SVB Leerink Outperform $6
Apr-29-22Initiated Cantor Fitzgerald Overweight $15
Dec-15-21Initiated Goldman Buy $15
Nov-08-21Initiated H.C. Wainwright Buy $14
Oct-28-21Initiated Citigroup Buy $11
Oct-26-21Initiated Truist Buy $15
Oct-26-21Initiated Jefferies Buy $10
Oct-26-21Initiated Cowen Outperform
Jun-28-22 06:27AM  
Jun-15-22 04:30PM  
May-24-22 06:00AM  
May-19-22 04:30PM  
May-16-22 07:00AM  
May-09-22 11:16AM  
May-02-22 07:00AM  
Apr-20-22 07:00AM  
Apr-13-22 07:00AM  
Mar-25-22 08:01AM  
Mar-24-22 07:00AM  
Mar-11-22 04:45PM  
Mar-07-22 11:18AM  
Feb-28-22 06:01AM  
Feb-14-22 07:00AM  
Feb-07-22 07:00AM  
Jan-25-22 04:30PM  
Jan-05-22 04:30PM  
Dec-16-21 10:00AM  
Nov-15-21 07:00AM  
Nov-08-21 04:45PM  
Nov-04-21 03:25PM  
Oct-29-21 07:52AM  
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kumar RakhiChief Accounting OfficerJun 23Sale4.341,6357,096146,021Jun 27 07:00 PM
Venker EricPresident & COOJun 23Sale4.3416,40271,1851,116,590Jun 27 07:00 PM
Gline MatthewCEOJun 23Sale4.3419,85586,1711,244,802Jun 27 07:00 PM
Kumar RakhiChief Accounting OfficerMay 20Sale3.7012,12744,870147,656May 24 07:00 PM
Venker EricPresident & COOMay 20Sale3.70136,421504,7581,132,992May 24 07:00 PM
Gline MatthewCEOMay 20Sale3.70139,791517,2271,264,657May 24 07:00 PM
Dexcel Pharma Technologies Ltd10% OwnerApr 25Buy3.918,60033,63598,849,443Apr 26 06:48 AM
Gline MatthewCEOApr 25Sale3.848,50932,6751,404,448Apr 27 07:00 PM
Venker EricPresident & COOApr 25Sale3.845,10719,6111,269,413Apr 27 07:00 PM
Kumar RakhiChief Accounting OfficerApr 25Sale3.847032,700159,783Apr 27 07:00 PM
Dexcel Pharma Technologies Ltd10% OwnerApr 22Buy3.8331,685121,31998,840,843Apr 26 06:48 AM
Gline MatthewCEOMar 30Sale4.8433,686163,0401,438,211Apr 01 06:00 PM
Kumar RakhiChief Accounting OfficerMar 30Sale4.842,48612,032162,563Apr 01 06:00 PM
Venker EricPresident & COOMar 30Sale4.8419,33693,5861,289,612Apr 01 06:00 PM
Venker EricPresident & COOMar 25Sale5.0680,045405,0281,308,948Mar 29 06:31 PM
Gline MatthewCEOMar 25Sale5.0635,386179,0531,471,897Mar 29 06:29 PM
Kumar RakhiChief Accounting OfficerMar 25Sale5.067,28136,842165,049Mar 29 06:27 PM
Gline MatthewCEOMar 18Sale5.1382,006420,6911,507,283Mar 22 09:00 PM
Kumar RakhiChief Accounting OfficerMar 18Sale5.132,15311,045172,330Mar 22 09:00 PM
Gline MatthewCEOMar 07Sale5.5292,324509,6281,589,289Mar 09 09:45 PM
Kumar RakhiChief Accounting OfficerMar 07Sale5.523,09117,062174,483Mar 09 09:45 PM